Our Science
Our initial product candidate, itolizumab, is a first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway. The CD6-ALCAM signaling pathway plays a central role in the modulation of effector T cells (Teff cells). Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe itolizumab may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.